Barbara Karakyriakou

Christensen lab

Barbara Karakyriakou graduated cum laude from Harvard University with a Bachelor of Liberal Arts in the field of Biology and minors in Mathematics and Computer Science. For two academic years, Barbara held special student status in the department of Biostatistics at Harvard where she pursued graduate studies. Following her graduation from Harvard, Barbara joined the Massachusetts General Hospital Cancer Center as a research associate specializing in epigenetics. During this time, she studied the role of the chromatin regulators CBP/p300 in multiple myeloma and prostate cancer, and she developed a strong interest in the epigenetic multiprotein complexes SWI/SNF and PRC2 which have been associated with tumor progression in several types of human cancers.  When not in the lab, Barbara enjoys going to the movies, theater, modern art museums, and car racing events. She also likes cooking, especially traditional Greek dishes using recipes from her paternal grandmother, who she was named after.

Contact

Barbara.Karakyriakou.GR@dartmouth.edu
6178206930
HB Hinman Box 7560

Selected Publications

  • Targeted degradation of the enhancer lysine acetyltransferases CBP and p300, Raghu Vannam, Jan Sayilgan, Samuel Ojeda, Barbara Karakyriakou, Eileen Hu, Johannes Kreuzer, Robert Morris, Xcanda Ixchel Herrera Lopez, Sumit Rai, Wilhelm Haas, Michael Lawrence, Christopher J Ott, Publication date 2021/4/15, Cell Chemical Biology, Volume 28, Issue 4, Pages 503-514. e12, Cell Press https://doi.org/10.1016/j.chembiol.2020.12.004, Total citations 40

    Collateral lethality between HDAC1 and HDAC2 exploits cancer-specific NuRD complex vulnerabilities, Yuxiang Zhang, David Remillard, Ugoma Onubogu, Barbara Karakyriakou, Joshua N Asiaban, Anissa R Ramos, Kirsten Bowland, Timothy R Bishop, Christopher J Ott, Michalina Janiszewska, Benjamin F Cravatt, Michael A Erb, Publication date 2022/1/1, bioRxiv, Cold Spring Harbor Laboratory, https://doi.org/10.1101/2022.05.30.493851, Total citations 1

    Targeted degradation of the enhancer lysine acetyltransferases CBP and p300, Samuel Ojeda, Raghu Vannam, Jan Sayilgan, Barbara Karakyriakou, Eileen Hu, Johannes Kreuzer, Robert Morris, Xcanda Ixchel Herrera Lopez, Sumit Rai, Wilhelm Haas, Michael Lawrence, Christopher J Ott, Publication date 2021/7/1, Journal Cancer Research, Volume 81, Issue 13_Supplement, Pages 1146-1146, Publisher The American Association for Cancer Research, https://doi.org/10.1158/1538-7445.AM2021-1146